Humacyte, Inc. (NASDAQ:HUMAW – Get Free Report) traded down 5.8% during mid-day trading on Thursday . The stock traded as low as $1.09 and last traded at $1.13. 10,447 shares changed hands during mid-day trading, a decline of 31% from the average session volume of 15,111 shares. The stock had previously closed at $1.20.
Humacyte Stock Down 3.5 %
The stock has a fifty day moving average of $1.57 and a 200-day moving average of $1.76.
Humacyte Company Profile
Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
See Also
- Five stocks we like better than Humacyte
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Unity Stock: Is a True Turnaround Finally Taking Shape?
- Options Trading – Understanding Strike Price
- DuPont’s Electronics Spinoff: The Start of Something Big
- How Investors Can Identify and Successfully Trade Gap-Down Stocks
- The Trade Desk Crashes on Earnings, But Growth Catalysts Persist
Receive News & Ratings for Humacyte Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humacyte and related companies with MarketBeat.com's FREE daily email newsletter.
